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Abstract: The aim of this work was the purification and identification of the major 
angiotensin converting enzyme (ACE) inhibitory peptides produced by enzymatic 
hydrolysis of a protein concentrate recovered from a cuttlefish industrial manufacturing 
effluent. This process consisted on the ultrafiltration of cuttlefish softening wastewater, 
with a 10 kDa cut-off membrane, followed by the hydrolysis with alcalase of the retained 
fraction. Alcalase produced ACE inhibitors reaching the highest activity (IC50 = 76.8 ± 
15.2 μg mL−1) after 8 h of proteolysis. Sequential ultrafiltration of the 8 h hydrolysate with 
molecular weight cut-off (MWCO) membranes of 10 and 1 kDa resulted in the increased 
activity of each permeate, with a final IC50 value of 58.4 ± 4.6 μg mL
−1
. Permeate 
containing peptides lower than 1 kDa was separated by reversed-phase high performance 
liquid chromatography (RP-HPLC). Four fractions (A–D) with potent ACE inhibitory 
activity were isolated and their main peptides identified using high performance liquid 
chromatography coupled to an electrospray ion trap Fourier transform ion cyclotron 
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resonance-mass spectrometer (HPLC-ESI-IT-FTICR) followed by comparison with 
databases and de novo sequencing. The amino acid sequences of the identified peptides 
contained at least one hydrophobic and/or a proline together with positively charged 
residues in at least one of the three C-terminal positions. The IC50 values of the fractions 
ranged from 1.92 to 8.83 μg mL−1, however this study fails to identify which of these 
peptides are ultimately responsible for the potent antihypertensive activity of  
these fractions. 
Keywords: ultrafiltration; proteolysis; ACE inhibitory peptides; cuttlefish byproducts; 
peptide identification; HPLC-ESI-MS 
 
1. Introduction 
Cardiovascular diseases (CVD) are the main cause of death globally, accounting for approximately 
17 million deaths a year, nearly one third of the total [1]. According to the World Health Organization, 
most cardiovascular diseases can be prevented by addressing risk factors, such as tobacco use, 
unhealthy diet and obesity, physical inactivity, high blood pressure, diabetes, and raised lipids [2]. 
Among all CVD, complications of hypertension account for 9.4 million deaths worldwide every  
year [3] and are the most common risk factors of heart diseases. Thus, hypertension is now considered 
a major health problem worldwide. 
Blood pressure is regulated by the renin-angiotensin system, wherein, the angiotensin converting 
enzyme (ACE) hydrolyses biologically inactive angiotensin I to the potent vasoconstrictor angiotensin 
II, responsible for the increase in the arterial pressure. At present, the renin-angiotensin system has 
become a key target for drugs combating hypertension [4] and, more specifically, various synthetic 
ACE inhibitors are widely used to treat cardiovascular disorders. However, these synthetic drugs have 
been described to have some side effects [5] and, thus, natural sources of ACE inhibitors are being 
investigated as a milder but effective alternative for the control of high blood pressure. Among the 
origins of these molecules are food-derived peptides from different sources, such as cheese whey [6], 
gelatin [7], and different meat and fish proteins [8].  
Marine biodiversity is a valuable source of molecules with diverse biological activities. Hence, 
interest has focused on the search of bioactive compounds, including ACE inhibitors, from marine 
sources. Peptides with ACE-inhibitory activity have been isolated from different marine species 
including shrimp [9], sole [10], cuttlefish [11,12], and salmon [13], among others.  
However, a more sustainable alternative providing high-value bioactive compounds is the use of 
fish byproducts. Among waste materials, fish processing wastewaters have been recently studied as 
starting materials to obtain ACE inhibitory peptides. Recently a functional concentrate from industrial 
shrimp (Penaeus spp.) cooking juice with antioxidative and antihypertensive (ACE-inhibitory) 
capacity has been obtained by Pérez-Santín et al. [14]. In addition, a screening study of different 
cuttlefish industrial processing wastewaters demonstrated the great potential of ultrafiltration  
(UF)-fractionation followed by proteolysis of cuttlefish protein concentrates as a source of peptide 
mixtures with antihypertensive and antioxidant activity [15].  
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The purpose of the present study was to purify and identify the major ACE inhibitory peptides 
produced by enzymatic hydrolysis of proteins recovered by UF from cuttlefish softening wastewater. 
For that purpose, the ACE inhibitory peptides from a cuttlefish byproduct hydrolysate were 
fractionated by sequential ultrafiltration using 10 and 1 molecular weight cut-off (MWCO) 
membranes. The most active fractions in the 1 kDa permeate were isolated by reversed-phase high 
performance liquid chromatography (RP-HPLC), their ACE-inhibitory activity quantified and the main 
peptides were identified by mass spectrometry. 
2. Results and Discussion 
2.1. Protein Recovery by Ultrafiltration-Diafiltration (UF-DF) 
The wastewater used in this work was the result of successive cooking operations using the same 
water in order to obtain a high initial protein concentration. For this reason, the protein content was 
significantly higher than others previously reported for cuttlefish processing effluents [16,17]. Protein 
concentration in cuttlefish softening wastewater was 11.5 ± 0.34 g L
−1
 and reached 95.42 ± 1.22 g L
−1
 
of protein content after ultrafiltration-diafiltration (UF-DF) at 10 kDa. As can be seen in Figure 1, 
Equation (1) was able to simulate the DF process and parameter determinations were always 
significant (Student’s t test, α = 0.05). Results of UF-DF using this cut-off membrane showed protein 
retentions higher than 95% of the initial protein content in the retentate and an overall concentration 
factor (fc) above 4.0.  
Figure 1. Protein recovery from cuttlefish wastewater by UF-DF at 10 kDa molecular 
weight cut-off (MWCO). Left: concentration of retained protein in linear relation with the 
volumetric concentration factor (fc) showing experimental data (points) and theoretical 
profiles (discontinuous line). Right: Progress of protein (○) retention with the increase of 
diavolume from DF process (D). For clarity, confidence intervals (in all cases less than 5% 
of the experimental mean value; α = 0.05; n = 2) were omitted. Equation (1) was used to fit 
the experimental data. 
 
This result slightly improves previously published data in the treatment of cuttlefish effluents using 
membrane technology. An 85% reduction in the chemical oxygen demand (COD) of cuttlefish 
processing wastewater was observed after nanofiltration using a 550 Da cellulose acetate  
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membrane [16]. On the other hand, a similar protein retention rate (78%) was reported in the 
microfiltration associated to ultrafiltration (15 kDa MWCO) of cuttlefish effluents using ceramic 
membranes [17]. All these studies consistently indicate a great efficiency of membrane technology for 
protein concentration. The use of these byproducts as a source of protein contributes to improving 
depuration of industrial wastewaters, reducing the treatment costs, and decreasing their  
contaminating effects. 
2.2. ACE Inhibitory Activity of Cuttlefish Hydrolysate and Their UF Fractions 
To obtain the ACE inhibitors, the cuttlefish protein concentrate was hydrolysed using alcalase 
according to optimal conditions previously reported for this substrate [12]. The extent of protein 
degradation by the proteolytic enzyme was estimated by assessing the degree of hydrolysis (DH) 
(Equation (2)). According to this calculation a high DH was observed from the beginning of the 
digestion, reaching a final value of 37.8% ± 0.4% after 8 h of proteolysis (Table 1).  
Table 1. Degrees of hydrolysis (DH) after 0.5, 2, and 8 h digestion with alcalase of a 
cuttlefish wastewater protein concentrate. Angiotensin converting enzyme (ACE) 
inhibitory activity (IACE (%)) and IC50 values (μg mL
−1
) of these hydrolysates, as well as 
retentates obtained by 10 and 1 kDa membrane and permeate of 1 kDa from the 8 h 
hydrolysate. IACE (%) was calculated by Equation (3). Mean values and standard deviations 
from triplicate samples are shown. 
Values of DH, IACE (%) and IC50 for Hydrolysis and UF Processes 
 
DH (%) IACE (%) IC50 (μg mL
−1
) 
– 37.8 ± 0.4 292.5 ± 20.3 
     
Hydrolysis 
0.5 h 17.5 ± 0.2 76.2 ± 3.2 214.4 ± 27.3 
2 h 23.8 ± 1.8 80.4 ± 2.3 122.5 ± 13.1 
8 h 36.4 ± 0.9 92.1 ± 0.6 76.8 ± 15.2 
     
Ultrafiltration 
10 kDa retentate – 83.3 ± 0.6 273.9 ± 30.1 
1 kDa retentate – 94.6 ± 2.9 235.6 ± 20.2 
1 kDa permeate – 68.0 ± 1.4 58.4 ± 4.6 
Indeed, the highest levels of hydrolysis were greater than those obtained from cuttlefish muscle [18] 
and other seafood species [13] using this enzyme. As reported before [12], this difference might be 
attributed to the thermal treatment of proteins recovered by UF, which tends to increase the 
susceptibility of proteins to enzymatic hydrolysis due to their partial denaturation.  
ACE inhibitory activity improved with increasing time of hydrolysis, reaching maximal values 
(92.1% ± 0.6%) after 8 h of proteolysis (Table 1). In addition, a direct relationship between ACE 
inhibitory activity and DH was observed in a study evaluating the ACE inhibitory activities of 
cuttlefish muscle protein hydrolysates prepared by treatment with various bacterial proteases [18]. In 
fact, the authors obtained a lower inhibitory activity (51.5% ± 1.5%) from a cuttlefish protein 
hydrolysate prepared using alcalase with a DH of 12.5%, i.e., three-fold lower than the DH reported in 
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the present study. However, it must be noted that hydrolysis conditions and calculation methods for the 
DH and ACE inhibitory varied between both studies, making difficult the direct comparison of  
the results.  
To calculate IC50 values, dose-response curves (Figure 2) were plotted and accurately fitted by 
Equation (4), with coefficients of determination greater than 0.98. 
Figure 2. Left: Experimental data (symbols) for ACE-inhibitory activity of cuttlefish 
softening wastewater protein concentrate before (●) and after hydrolysis with alcalase for 
0.5 (○), 2 (), and 8 h (□). Right: Experimental data (symbols) for ACE-inhibitory activity 
of 10 kDa () and 1 kDa (▼) retentates and 1 kDa permeate (▲) from the 8 h 
hydrolysate. The dose-response curves (lines) were obtained by modeling experimental 
data to the Equation (4). 
 
Equation (4) allowed the direct determination of IC50 values using mathematical nonlinear fitting. 
The estimation of IC50 values using this model is more precise than direct interpolation or linear 
regression and allows the objective comparison between samples. This equation was consistent 
(Fisher’s F test; p < 0.05) and parameter estimations were always significant (Student’s t test,  
α = 0.05) (data not shown). According to this approach, IC50 decreased with increasing time of 
hydrolysis reaching the lowest value (maximal ACE inhibitory activity) after 8 h of hydrolysis. These 
differences revealed that the use of alcalase was efficient in releasing peptides with ACE inhibitory 
activity from cuttlefish protein concentrate. In fact, this endoprotease has been widely employed for 
the production of potent marine derived ACE inhibitors from sources as diverse as the algae Chlorella 
ellipsoidea [19], salmon byproducts [20], seaweed pipefish muscle protein [21], the sea cucumber 
Acaudina molpadioidea [22], and lizard fish [23]. This enzyme is also less expensive than others 
commercially available, thus, being a good candidate for the industrial production of bioactive 
hydrolysates from marine byproducts. Values of IC50 for ACE inhibitory activity of whole cuttlefish 
hydrolysates have being previously reported for various digestive proteases [11], including  
alcalase [18]. These values ranged from 1.19 to 2.31 mg mL
−1
, however the direct comparison with 
IC50 values in the present study (Table 1) is not possible due to differences in the hydrolysis conditions 
but, also, in the methodology employed for ACE inhibitory activity determination and calculation. 
C (µg mL-1)
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The 8 h hydrolysate, which led to the highest ACE inhibitory activity (lowest IC50), was 
fractionated in an attempt to isolate the active peptides. The use of UF has proven to be a valuable 
resource for hydrolysate fractionation, significantly decreasing the IC50 value of peptide mixtures 
obtained from different sources [6,24–26]. For this reason, the 8 h hydrolysate was sequentially 
ultrafiltered through membranes at 10 and 1 kDa MWCO (Figure 3). Then, permeate and retentates 
ACE inhibitory activity was determined. As summarized in Table 1, the lowest IC50 value was 
associated to 1 kDa permeate (58.4 ± 4.6 μg mL−1), indicating that the maximum contribution to  
ACE-inhibitory activity is due to the peptides with MW below 1 kDa. Similarly, the ACE inhibitory 
activity was significantly higher in the lowermost MW fraction (<1 kDa) from collagenous residues 
from squid skins hydrolyzed with esperase [25]. 
Figure 3. Process of ACE inhibitory peptide production from a protein enriched fraction 
recovered from cuttlefish wastewater by UF-DF at 10 kDa (Step 1) followed by hydrolysis 
with alcalase (0.4% v/v) for 8 h at 55 °C (Step 2). Then, the hydrolysate was fractionated 
using a sequentially UF through membranes of 10 (Step 3) and 1 kDa (Step 4). UFP: 
Permeates of UF; UFR: retentates of UF. 
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This observation is in good agreement with previous studies reporting greater in vitro activity of 
low than high molecular weight peptides from different protein origin [13,18].  
2.3. Identification of Major ACE Inhibitory Peptides 
The ACE inhibitory peptides in the 1 kDa permeate from cuttlefish hydrolysate were separated by 
RP-HPLC on a C18 column. The chromatogram (Figure 4) was divided into sixty-five fractions  
(2 mL) that were freeze-dried and their ACE inhibitory activity determined after resuspension in 
milliQ water and pH adjustment to 7.0. Four fractions showing the highest activity were collected 
separately under optimized separation conditions that allowed a better resolution of the peaks,  
i.e., lower flow rate and a narrower acetonitrile gradient. The separation procedure was successively 
repeated to obtain a sufficient protein concentration for further analysis. The most active fractions 
(Figure 4A–D) were freeze-dried and their ACE inhibitory activity and IC50 values determined  
(Table 2). 
Figure 4. Peptide profile of the 8 h hydrolysate that was permeated through the 1 kDa 
ultrafiltration membrane after RP-HPLC separation. Lines indicate the peaks 
corresponding to the four active fractions (A–D). 
 
The chemical characterization of each RP-HPLC fraction was carried out using mass spectrometry, 
in order to identify the main peptides contributing to the ACE inhibitory activity measured in these 
samples. According to these results (Table 2), among the four fractions only two (C and D) matched 
the protein databases and the other two fractions (A and B) had to be sequenced de novo.  
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Table 2. Major identified peptides corresponding to the four more active fractions after 
semi-preparative fractionation by reversed-phase high performance liquid chromatography 
(RP-HPLC) of the 1 kDa ultrafiltration permeate from the 8 h hydrolysate. The IC50  
(μg mL−1) value and the protein source of these fractions are shown. 
Fraction Peptides Protein Source Mass (Da) IC50 (μg mL
−1
) 
A GNALVFLLP  943.57 1.92 ± 0.40 
FALASSLVN  921.53 
SPSIAPAL  755.40 
GLFAAHRK  899.54 
FTPESLAI  877.50 
DAAIKTLTK  960.60 
MMQLRKA  877.50 
RALKIPAM  899.54 
FTVKPVSR  933.59 
SSSKAKKKP  960.60 
KAVPIAIL  824.58 
TRAASCP  705.30 
INKAVTGLK  943.57 
PEGSIRP  755.40 
B VEDAEVGKK  974.52 4.00 ± 0.19 
 FAGDDAPRA  919.43 
 AGSVNKSK  790.44 
 KAGSELGL  774.44 
 QSLEVSK  790.43 
 KEAEVSK  790.43 
 GAEVTVSK  790.43 
 QEVSLSK  790.43 
 AGEVSLSK  790.43 
 NFGCSVK  754.35 
 SVCGGFGK  754.35 
 AGDDPAR  701.32 
C ADQSEGALQK Myosin HC 1045.5 8.63 ± 0.86 
 ISEQEASQR Tropmyosin 1046.5 
 LGEGGRSTHE Myosin HC 1041.5 
 RLKEAENR Actin 981.5 
 TDQLGEGGRS Myosin HC 1018.5 
D DEDATGVIR Tn C 974.47 7.18 ± 2.44 
GTDPEDALRN Myosin RLC 1086.49 
GVNLEDAKRS Myosin HC 1087.56 
LTEAPLNPK Actin 981.55 
REDIDGNIK Myosin LCK 1058.54 
The peptides identified in the fractions C and D are derived from muscular protein fragments of the 
cuttlefish mantle. Softening of fish muscle consists on the heating and addition of salts to solubilize 
myofibrillar proteins, improving the water-fat-retention and leading to acceptable rigidity/elasticity of 
the muscle gels [27]. Thus, as expected and since the cuttlefish hydrolysate was prepared from a 
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protein concentrate recovered from softening wastewater, myofibrillar proteins, such as troponin, actin, 
and myosin were identified as protein sources from the identified peptides (Table 2). Antihypertensive 
peptides isolated from other squid proteins hydrolysates, such as collagen [27] and gelatin [7,28], have 
also been reported. These studies identified peptides sequences of the major ACE inhibitory fractions 
with a high content in proline, glycine, and leucine residues and suggesting the presence of this last 
amino acid could play an important role in the ACE-inhibitory activity [28]. 
As is known, peptide sequence greatly contributes to its biological activity. The structure–function 
relationship for ACE inhibitory peptides is not fully characterized, although recently published papers 
deal with the structure-activity relationships of di and tripeptides [29,30]. Some of the information 
available about this topic indicates that the three amino acids in the C-terminal peptide sequence are 
particularly important for their binding to ACE, as they might interact with the active site of the 
enzyme [31]. For instance, this enzyme prefers hydrophobic amino acids, including aromatic residues 
(phenylalanine, tryptophan, and tyrosine) and branched chain amino acids (valine, leucine, and 
isoleucine) in one of the three positions of the C-terminal [32]. In this study, all of the peptides 
identified in the four potent ACE inhibitory fractions contained at least one hydrophobic residue, being 
the most abundant branched chain amino acids (Table 2).  
On the other hand, ACE has low affinity for peptides with dicarboxylic amino acids in this position 
or those containing the amino acid proline in the penultimate position [33], although proline in final or 
penultimate position of the C-terminal peptide sequence promotes enzyme binding [34]. In fact, 
several identified ACE inhibitory peptides had a proline residue in one of these positions of  
C-terminal, although this is neither sufficient nor essential to confer activity [18]. Furthermore, the 
positively charged amino acids, such as arginine and lysine at the C-terminal sequences were also 
reported to contribute towards ACE inhibitory or antihypertensive effect [35]. As can be seen in  
Table 2, among the identified peptides many of them contained one of these residues in the C-terminal. 
This was especially evident in fraction B, where ten of the twelve peptides identified contained lysine 
or arginine in last position. In agreement with other published papers, these findings confirm that 
peptide sequences are greatly important to define their ACE inhibitory activity (IC50 values). However, 
the differences in the composition of the peptides identified in this study fail to explain the differences 
found in the ACE inhibitory activity and, thus, further studies are needed to define which of these 
peptides are ultimately responsible for the potent antihypertensive activity of these fractions. 
3. Experimental Section 
3.1. Cuttlefish Processing Wastewater 
Wastewater from the softening treatment during industrial manufacturing of cuttlefish was kindly 
provided by Frinova S.A., (Porriño, Galicia, Spain). The average content of suspended solids of this 
water was ranged among 0.3–0.7 g L−1 and the solid residue was around 10–15 g L−1. The water was 
decanted to discard the particulate matter, sampled for analytical determinations, and stored at −20 °C 
until further use.  
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3.2. Total Protein Analysis 
Protein concentration was determined by the bicinchoninic acid assay (BCA, Pierce, Rockford, IL, 
USA) using bovine serum albumin as standard. Briefly, 200 μL of the BCA working reagent were 
mixed with 25 μL of sample. The mixture was incubated for 30 min at 37 °C and the absorbance taken 
at 562 nm using a Multiskan Spectrum Microplate Spectrophotometer (Thermo Scientific, Waltham, 
MA, USA). 
3.3. Ultrafiltration-Diafiltration Process 
Cleaned cuttlefish wastewater was subjected to ultrafiltration-diafiltration using a Prep/Scale-TFF 
polyethersulfone cartridge (Millipore Corporation, Bedford, MA, USA) of 10 kDa molecular weight 
cut-off (MWCO). The operation mode was the following: an initial phase of ultrafiltration (UF) at  
40 °C with total recirculation of retentate was performed, immediately followed by a diafiltration (DF) 
process. During UF, the inlet pressure remained constant to determine the flow rate drops due to the 
increased concentration of protein in the retentate and to possible membrane fouling. The final 
retentate (after DF) was frozen at −20 °C for further hydrolysis and permeate from the DF phase  
was discarded. 
For the modeling of the membrane process, we assumed that in the DF with constant volume 
(filtration flow = water intake flow), the concentration (or the total amount) of a permeable solute in 
the retentate followed first order kinetics [15]:  
 0 exp 1fR R R s D       (1) 
where, R is the concentration of permeable protein in the retentate (% from the level at initial DF), R0 
the initial concentration (%), Rf is the final and asymptotic concentration (%), D is the relative 
diavolume (volume of added water/constant retentate volume) and s is the specific retention of protein 
with variation between 0 (the solute is filtered as the solvent) and 1 (the solute is totally retained). 
Thus, using normalized values (%): R0 + Rf = 100, being R0 = 0 if all protein is permeable.  
3.4. Preparation of Enzymatic Hydrolysates 
The cuttlefish wastewater concentrate (retentate) was pre-incubated at 55 °C for 10 min prior to 
enzymatic hydrolysis using Alcalase 2.4 L from Novo Co. (Novozyme Nordisk, Bagsvaerd, Denmark). 
The enzyme to substrate ratio (E/S) was 0.4% (v/w) in relation to retentate weight and the reaction was 
performed in a temperature-controlled water bath under constant magnetic stirring [12]. Samples were 
taken after 0.5, 2, and 8 h of hydrolysis, boiled for 15 min to inactivate the protease and then cooled in 
an ice-water bath for at least 30 min. Hydrolysates were centrifuged at 10,000× g for 15 min (4 °C) in 
an Avanti J-26 XP centrifuge (Beckman Coulter, Inc., Miami, FL, USA) and supernatants were stored  
at −20 °C until further analysis of their degree of hydrolysis and antihypertensive activity. 
3.5. Degree of Hydrolysis Determination 
The degree of hydrolysis (DH) was defined as the ratio of the released tyrosine to the initial tyrosine 
in the retentate [12], according to the following expression:  
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where, Ct is the tyrosine concentration (g L
−1
) of the hydrolysate at time t and C0 is the tyrosine 
concentration (g L
−1
) of the sample at time zero. Tyrosine was measured by the method described in 
Barker and Worgan [36].  
3.6. Angiotensin I-Converting Enzyme (ACE) Inhibition Assay 
The antihypertensive activity was determined using a modified version of the method described by 
Shalaby et al. [37] with N-[3-(2-Furyl) acryloyl]-L-phenylalanyl-glycyl-glycine (FAPGG) as substrate. 
Briefly, 10 μL of sample were mixed with 10 μL of ACE solution (0.5 U mL−1) in each well of a  
96-well microtiter plate. The reaction was started by adding 150 μL of substrate (0.88 mM FAPGG in 
50 mM Tris-HCl, pH 7.5, 0.3 M NaCl) pre-heated at 37 °C. The absorbance at 340 nm (A340) was 
acquired at time intervals of 30 s for 30 min in a Multiskan Spectrum Microplate Spectrophotometer 
(Thermo Scientific, Waltham, MA, USA). The control consisted of samples containing 10 μL of buffer 
(50 mM Tris-HCl, pH 7.5, 0.3 M NaCl) instead of protein hydrolysate. Samples and controls were 
performed in triplicate. 
ACE-inhibitory capacity (IACE) was calculated as a function of the average slope of decrease in 
absorbance with time and expressed as percent of enzyme inhibition according to the  
following expression: 
  1 100hACE
c
A
I %
A


 
   
 
 (3) 
where, IACE is the ACE-inhibitory capacity (%), ρAh is the slope of decrease in A340 in the presence of 
inhibitor (hydrolysate) and ρAc is the slope of decrease in A340 in the absence of inhibitor (control).  
For the calculation of the protein concentration causing a 50% ACE inhibition (IC50), dose-response 
curves were obtained assaying different concentrations of hydrolysates. IC50 values were calculated by 
fitting the dose-response curves of IACE vs. protein concentration to a mechanistic model developed by 
Estévez et al. [6]: 
 
 
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 
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           50
100 1
1
2 1
 (4) 
where, K is the maximum IACE (%), C is the protein concentration (μg mL
−1
) and IC50 is the 
concentration for semi-maximum response (μg mL−1). Km is the Michaelis–Menten constant of 
FAPGG and S is the concentration of this substrate in the assay, respectively. Both Km and S are 
constants under these experimental conditions, with values of 182 μg mL−1 and 310 μg mL−1, 
respectively [6]. 
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3.7. Isolation of Major ACE-Inhibitory Peptides 
The 8-h-hydrolysate was further ultrafiltered to remove peptides with high molecular weight. UF 
were carried out in a stirred UF cell module (Millipore Corporation, Bedford, MA, USA) under a 
nitrogen flow pressure of 40 psi at room temperature using separately 10 and 1 kDa MWCO 
membranes (Millipore Corporation, Bedford, MA, USA). Firstly, the hydrolysate was ultrafiltrate 
using a 10 kDa MWCO membrane followed by further fractionation of the 10 kDa permeate through a 
1 kDa MWCO membrane. Samples from 10 and 1 kDa retentates and 1 kDa permeate were collected 
and protein concentration and ACE-inhibitory activity (IC50) were determined. 
The 1 kDa permeate was separated by RP-HPLC on an Agilent 1200 series system (Agilent, 
Waldbronn, Germany) using an ACE 5 C18 column (10 × 250 mm, 5 μm). Peptides were eluted and 
monitored at 220 nm using water containing 0.1% trifluoric acetic acid (TFA) (mobile phase A) and 
acetonitrile with 0.1% TFA (mobile phase B), with a linear gradient of acetonitrile (0%–50% v/v) 
during 50 min. The ACE inhibitory activity was determined in 2 mL fractions collected at a flow rate 
of 2.5 mL min
−1
. Those fractions showing the highest ACE inhibitory activity were collected using an 
Agilent Zorbax Eclipse C18 column (4.6 × 250 mm, 5 μm) with a linear gradient of acetonitrile  
(5%–30% v/v) at a flow rate of 0.75 mL min−1 during 30 min. According to the chromatographic 
peptide profile obtained, four fractions from ten samples were defined and collected manually, frozen 
at −80 °C, and lyophilized for further protein quantitation, antihypertensive activity determination, and 
mass spectrometry identification analysis. 
3.8. Mass Spectrometry Analysis of ACE-Inhibitory Peptides 
The freeze-dried fractions were diluted in 1 mL of 1% ACN, 0.1% formic acid (FA) and 2 μL 
aliquots were analyzed using a C18 column coupled to an electrospray ion trap Fourier transform ion 
cyclotron resonance-mass spectrometer (ESI-IT-FTICR, Thermo Fisher Scientific, Bremen, Germany). 
A data dependent fragmentation method consisting of cycles of high resolution full scan spectra 
followed by ion trap fragmentation and detection of the five most intense masses was used for 
identification purposes. The chromatographic system (Agilent 1200 series, Waldbronn, Germany) was 
equipped with an Agilent SB C-18 column (0.5 × 150 mm, 5 μm). A very slow elution program, 
namely, 0/5, 6/5, 7/10, 32/40, 34/90 (min/%B, being mobile phase A 5% ACN, 0.1% FA and mobile 
phase B pure ACN, 0.1% FA), at a flow of 20 μL min−1, was optimized to enhance the separation of 
the low hydrophobic species fractionated in the previous semi-preparative chromatographic dimension. 
3.9. Mass Spectrometry Data Processing 
MS/MS spectra were searched using SEQUEST-SORCERER™ 2 package (Sage-N Research Inc., 
Milpitas, CA, USA), against the UniProt/SwissProt database (release 2012_10; 455.545 entries), which 
also included their respective decoy sequences. The following constraints were used for the searches: 
semi-tryptic cleavage with up to two missed cleavage sites and tolerances 1.0 Da for precursor ions 
and 0.5 Da for MS/MS fragments ions. The variable modifications allowed were methionine oxidation 
(m), carbamidomethylation of Cys and acetylation of the N-terminus of the protein (N-Acyl). The 
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database search results were subjected to statistical analysis with the PeptideProphet algorithm  
(v.4.4) [38]. The FDR was kept below 1%.  
De novo sequencing was performed by manual interpretation of the ion series of the spectra with aid 
of the software packages: DeNovoX (Thermo Scientific, Waltham, MA, USA) and PEAKS Studio 6.0 
(Bioinformatics Solutions Inc., Waterloo, Ontario, Canada). The parameters used for both programs 
were as follows: selection of the peptide charge (1+, 2+, 3+), tolerances of 0.3–0.5 Da for precursor 
and fragments ions, use or not of trypsin or Glu-C as proteases and three variable modifications: 
Methionine oxidation (m), carbamidomethylation of Cys and acetylation of the N-terminus of the 
protein (N-Acyl). 
4. Conclusions 
In this study, ACE inhibitory peptides were produced from cuttlefish byproduct protein hydrolysate 
using a combination of membrane technology (UF-DF) and enzyme proteolysis using alcalase. The 
sequential ultrafiltration with two membranes cut-offs (10 and 1 kDa) led to recover a remarkable 
antihypertensive activity. The most bioactive peptides were subsequently separated by means of  
RP-HPLC and characterized by HPLC-ESI-IT-FTICR. The procedure developed in the present work 
demonstrated to be a feasible biotechnological approach to produce antihypertensive peptides from 
marine wastes and to help in the depuration and valorization of wastewaters generated by marine food 
processing. Nevertheless, further studies (peptide synthesis, re-chromatography of the HPLC  
fractions, etc.) are needed in order to identify which among these peptide mixtures are responsible for 
the observed activity. 
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